文献速递前列腺癌

预后评分与阿比特龙在初治转移性去势抵抗性前列腺癌中的获益

Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2021-08-06

本研究在COU-AA-302试验中验证Armstrong预后模型对初治mCRPC患者的预后价值。共分析1088例患者,风险评分与总生存相关(tAUC 0.733),低风险患者从阿比特龙获益更显著。

要点

  • Armstrong模型在COU-AA-302中验证,风险评分与OS相关(tAUC 0.733)。
  • 低风险患者接受阿比特龙 vs 安慰剂2年OS率82% vs 74%。
  • 风险组与治疗交互作用显著(OS p=0.007,rPFS p=0.009)。

核心结论

  • Armstrong风险模型在初治AR信号抑制剂治疗患者中具有预后价值。
  • 阿比特龙在低风险、侵袭性较低的患者中获益更大。

研究设计与样本

  • COU-AA-302试验的事后分析(NCT00887198),共分析1088例mCRPC患者。
  • 应用Armstrong预后模型,按风险因素数量分为低危(≤3)、中危(4-6)、高危(7-10)。

主要发现

  • 风险评分与总生存相关,tAUC为0.733。
  • 低危患者占49%,中危占41%。
  • 风险类别与OS显著相关(HR:2.3;95%CI:1.9-2.4;p<0.001)。
  • 风险类别与rPFS显著相关(HR:1.7;95%CI:1.5-1.8;p<0.001)。
  • 风险类别与PSA-PFS显著相关(HR:1.7;95%CI:1.5-1.9;p<0.001)。

关键数值与推荐

  • 低危患者阿比特龙 vs 安慰剂OS HR:0.73(95%CI:0.59-0.89;p=0.009)。
  • 中危患者OS HR:0.97(95%CI:0.79-1.21;p=0.9)。
  • 高危患者OS HR:1.35(95%CI:0.80-2.28;p=0.5)。
  • 2年OS率:低危82% vs 74%,中危55% vs 52%,高危28% vs 31%。

临床怎么用

  • Armstrong风险模型可用于初治mCRPC患者的预后分层。
  • 低风险患者可能从阿比特龙治疗中获益更多。

局限性

  • 事后分析,需进一步研究确定Armstrong风险组在mCRPC治疗选择中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most available prognostic nomograms in metastatic castration-resistant prostate cancer (mCRPC) are derived from datasets not representative of the current treatment landscape. A prognostic nomogram for first-line mCRPC treatment was developed from patients treated in the PREVAIL study. OBJECTIVE: To validate the Armstrong model in the COU-AA-302 trial. DESIGN, SETTING, AND PARTICIPANTS: A post hoc analysis of mCRPC patients treated in the COU-AA-302 trial was carried out (NCT00887198). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The Armstrong prognostic model was applied to patients treated in COU-AA-302. A continuous risk score was derived from coefficients from the original model. Time-dependent area under the curve (tAUC) was used to evaluate the overall predictive ability of the model. Patients were categorized according to the number of risk factors present into those at a low (three or fewer risk factors), intermediate (four to six risk factors), and high (seven to ten risk factors) risk. The association with survival was assessed with Cox regression models. Interaction tests were used to assess the impact of treatment arm in each of the prognostic groups. RESULTS AND LIMITATIONS: A total of 1088 patients were analyzed. The risk score was associated with overall survival (OS; tAUC 0.733). Most patients were at a low (49%) or intermediate (41%) risk. Risk category was significantly associated with OS (hazard ratio [HR]: 2.3; 95% confidence interval [CI]: 1.9-2.4; p < 0.001), radiographic progression-free survival (rPFS; HR: 1.7; 95% CI: 1.5-1.8; p < 0.001), and prostate-specific antigen progression-free survival (HR: 1.7; 95% CI: 1.5-1.9; p < 0.001). A significant interaction between risk group and OS (p = 0.007) and rPFS (p = 0.009) was observed. Survival was superior in low-risk patients (HR: 0.73; 95% CI: 0.59-0.89; p = 0.009), but similar in intermediate-risk (HR: 0.97; 95% CI: 0.79-1.21; p = 0.9) and high-risk (HR: 1.35; 95% CI: 0.80-2.28; p = 0.5) patients. Two-year OS rates in abiraterone versus placebo were 82% versus 74% in low-risk, 55% versus 52% in intermediate-risk, and 28% versus 31% in high-risk patients. CONCLUSIONS: We validate the prognostic value of the Armstrong risk model in patients treated with first-line androgen receptor signaling inhibitors. Abiraterone provided a greater benefit in low-risk patients with less aggressive disease. Further research is needed to establish the role of Armstrong risk groups for treatment selection in mCRPC patients. PATIENT SUMMARY: In this report, we validated the Armstrong nomogram in the COU-AA-302 trial population. We found a similar prognostic performance to that of the original model. Good-risk patients received the greatest benefit from abiraterone.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lorente D, Llacer C, Lozano R, et al. Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer. Eur Urol. 2021. PMID: 34373138. doi:10.1016/j.eururo.2021.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。